ProKidney reports Q2 2023 net loss of $34.8M; cash at $446.1M

PROKIDNEY CORP.

Net loss before noncontrolling interest $34.8M for Q2 2023 vs $22.1M in Q2 2022.
R&D expenses $26.4M (up from $11.6M) driven by Phase 3 trial and manufacturing expansion.
Cash, equivalents and marketable securities $446.1M as of June 30, 2023, down from $490.3M at Dec 31, 2022.
Purchased 210,000 sq ft Greensboro facility; $458M investment planned by 2027 with $33.7M in tax incentives.
Phase 3 proact 1 enrolling; interim data expected end 2024; proact 2 enrollment expected H2 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROKIDNEY CORP. reported second quarter ended June 30, 2023 results: net income Net loss before noncontrolling interest was $34.8 million.

Period: second quarter ended June 30, 2023
Net income: Net loss before noncontrolling interest was $34.8 million
Result: reported results

Exact text from the filing

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

View on SEC.gov

Browse all earnings releases →

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0000950170-23-041417

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.